GlassScriptPhysician profile
Delia Behpour
NPI 1831840552
$2,123.17
in general payments reported to CMS, 2019-2025
29 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $325 · 2024: $1,271 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.19 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $276.93 | 2024-2025 | |
| Daiichi Sankyo INC. | $210.30 | 2024-2025 | Enhertu, Vanflyta |
| Abbvie INC. | $187.33 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $158.10 | 2023-2025 | Reblozyl, Opdivo |
| Neurelis, INC. | $123.50 | 2025 | Valtoco |
| Genentech USA, INC. | $117.04 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Janssen Biotech, INC. | $109.42 | 2024-2025 | Rybrevant, Carvykti, Akeega |
| Novartis Pharmaceuticals Corporation | $105.33 | 2024-2025 | |
| Stemline Therapeutics INC. | $87.76 | 2023 | Orserdu |
| Seagen INC. | $69.99 | 2024 | |
| Eisai INC. | $67.44 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $59.41 | 2024 | Libtayo |
| Adaptive Biotechnologies Corporation | $53.94 | 2024 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $49.26 | 2024-2025 | Fruzaqla, Iclusig |
| Astrazeneca Pharmaceuticals LP | $48.13 | 2023-2025 | Calquence |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $44.83 | 2024 | Brukinsa |
| Lilly USA, LLC | $42.30 | 2024-2025 | Verzenio, Retevmo, Jaypirca |
| Sobi, INC | $40.11 | 2024-2025 | |
| Novocure INC. | $38.28 | 2024 | Optune, Optune Lua (Novottf-200t) |
| Celgene Corporation | $30.31 | 2024 | Reblozyl |
| Astellas Pharma US INC | $29.45 | 2025 | Xtandi |
| Kyowa Kirin, INC. | $25.96 | 2024 | Poteligeo |
| Merck Sharp & Dohme LLC | $25.52 | 2025 | Keytruda |
| Incyte Corporation | $24.31 | 2024 | Jakafi |
| Agios Pharmaceuticals, INC. | $22.98 | 2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $22.75 | 2024 | Cosela |
| Tersera Therapeutics LLC | $22.51 | 2024 | Quzyttir |
| Genmab U.S., INC. | $16.26 | 2024 | Epkinly |
| Glaxosmithkline, LLC. | $13.72 | 2024 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delia Behpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.